Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open‐label phase 3 study

A phase 3, multicenter, open‐label, 52‐week study investigated the efficacy and safety of adalimumab 80 mg at week 0 followed by adalimumab 40 mg every other week (option to escalate to 80 mg when necessary) in Japanese patients with generalized pustular psoriasis (GPP). Adults (aged 15–75 years) wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Akimichi, Yamazaki, Fumikazu, Matsuyama, Takashi, Takahashi, Kenzo, Arai, Satoru, Asahina, Akihiko, Imafuku, Shinichi, Nakagawa, Hidemi, Hasegawa, Yuichi, Williams, David, Matsuda, Naoto, Kitamura, Susumu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585693/
https://www.ncbi.nlm.nih.gov/pubmed/30302793
http://dx.doi.org/10.1111/1346-8138.14664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585693/
https://www.ncbi.nlm.nih.gov/pubmed/30302793
http://dx.doi.org/10.1111/1346-8138.14664

Ejemplares similares